ABRILADA. Let’s go.
Injection: 40 mg/0.8 mL, 20 mg/0.4 mL
|
Not actual patient. |
Pfizer’s FDA-approved, citrate-free, interchangeable biosimilar to Humira® (adalimumab)* |
Are you starting treatment with ABRILADA?
Are you switching to ABRILADA from Humira?
If eligible, you may pay as little as $0 for ABRILADA treatment.
Enrollment required. Limits, terms, and conditions apply.†
ABRILADA IS APPROVED TO
REDUCE THE SIGNS AND SYMPTOMS OF: |
|
|
Moderate to severe rheumatoid arthritis (RA) in adults. ABRILADA can be used alone, with methotrexate, or with certain other medicines. ABRILADA may prevent further damage to your bones and joints and may help your ability to perform daily activities. |
|
Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. ABRILADA can be used alone or with methotrexate. |
|
Psoriatic arthritis (PsA) in adults. ABRILADA can be used alone or with certain other medicines. ABRILADA may prevent further damage to your bones and joints and may help your ability to perform daily activities. |
|
Ankylosing spondylitis (AS) in adults. |
|
Moderate to severe hidradenitis suppurativa (HS) in adults. |
TREAT: |
|
|
Moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older. |
|
Moderate to severe ulcerative colitis (UC) in adults. It is not known if adalimumab products are effective in people who stopped responding to or could not tolerate anti-TNF medicines. |
|
Moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate. |
|
Uveitis (UV) in adults: non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye). |
*ABRILADA is interchangeable for the indications of use, dosage forms, strengths, and routes of administration described in Prescribing Information.
† Terms and Conditions: By using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions below:
The Pfizer enCompass® Co-Pay Assistance Program for ABRILADA is not valid for patients that are enrolled in a state- or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). Program offer is not valid for cash-paying patients. Patients prescribed ABRILADA for adolescent hidradenitis suppurativa (HS), pediatric uveitis, or pediatric ulcerative colitis are not eligible for this co-pay savings program. With this program, eligible patients may pay as little as $0 co-pay per ABRILADA treatment, subject to a maximum benefit of $4,000-$14,000 per calendar year for out-of-pocket expenses for ABRILADA, depending on your insurance, including co-pays or coinsurances. The amount of any benefit is the difference between your co-pay and $0. After the maximum benefit, you will be responsible for the remaining monthly out-of-pocket costs. Patient must have private insurance with coverage of ABRILADA. This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other private health or pharmacy benefit programs. You must deduct the value of this assistance from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the program, as may be required. You should not use the program if your insurer or health plan prohibits use of manufacturer co-pay assistance programs. This program is not valid where prohibited by law. The benefit under the program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third-party payers, pharmacy benefit managers, or the agents of either. This program cannot be combined with any other external savings, free trial, or similar offer for the specified prescription (including any program offered by a third-party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs). Third-party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the program. Co-pay card will be accepted only at participating pharmacies. If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer. The rebate form can be found at https://patient.pfizeriandicopay.com. This program is not health insurance. This program is good only in the U.S. and Puerto Rico. This program is limited to 1 per person during this offering period and is not transferable. This offer cannot be redeemed more than once per 30 days per patient. No other purchase is necessary. Data related to your redemption of the program assistance may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other assistance redemptions and will not identify you. Pfizer reserves the right to rescind, revoke, or amend this program without notice. This program may not be available to patients in all states. For more information about Pfizer, visit www.pfizer.com. For more information about the Pfizer enCompass Co-Pay Assistance Program, call Pfizer enCompass at 1-844-722-6672, or write to Pfizer enCompass Co-Pay Assistance Program at 2730 S. Edmonds Lane, Suite 300, Lewisville, TX 75067. Card and Program expire 12/31/2024.